Upstate Active Clinical Trials
Study Title:A Phase 2/3Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK) Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered with an Optimized Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Viroligically Suppressed Pediatric Subjects.
What is the purpose of the study? (in Layman's terms, please describe the study)To evaluate the steady state pharmacokinetics (PK) and confirm the dose of cobicistat-boosted atazanavir (ATV/co) or cobicistat-boosted Darunavir (DRV/co) in HIV-1 antiretroviral experienced pediatric participants between the ages of 3 Months and less than 18 Years.
Upstate Institutional Review Board (IRB) Number:518998
Patient Age Group:Children
Principal Investigator:Leonard B Weiner
Who can I contact for more information?
Name: Wendy A Holz